Cervical cancer is the fourth most common cancer in women worldwide, with roughly 660,000 new cases and 350,000 deaths in 2022. In the United States, it’s far less common thanks to widespread screening and vaccination: about 13,000 new cases are diagnosed each year, and around 4,000 women die from it annually.
Those numbers tell two very different stories depending on where you live, your access to screening, and whether you’ve been vaccinated against HPV. Here’s what the data actually looks like.
Cervical Cancer Rates in the United States
Among American women, the overall incidence rate is roughly 7 to 10 new cases per 100,000 women each year, depending on race and ethnicity. Hispanic women have the highest incidence at 10.1 per 100,000, followed by non-Hispanic Black women at 8.2 and non-Hispanic white women at 6.8. To put that in perspective, breast cancer strikes about 130 per 100,000 women annually, making cervical cancer comparatively uncommon in the U.S.
That relatively low number is a direct result of screening. The Pap test, introduced decades ago, led to a 70% decrease in both cervical cancer incidence and deaths in countries where it became routine. Before widespread screening existed, cervical cancer was one of the leading causes of cancer death among American women.
Who Is Most at Risk
More than 9 out of every 10 cervical cancers are caused by HPV, a sexually transmitted infection that is extremely common on its own. Most HPV infections clear without causing problems, but certain high-risk strains can trigger cell changes in the cervix that, over years or decades, develop into cancer.
Race and ethnicity correlate with significant differences in outcomes, largely driven by gaps in access to screening and follow-up care. Non-Hispanic Black women face the highest death rate at 2.9 per 100,000, compared to 2.3 for Hispanic women and 2.0 for non-Hispanic white women. Black and Hispanic women are also more likely to be diagnosed at later stages, when the cancer has already spread beyond the cervix. Women in rural areas tend to have higher rates than those in urban areas as well, regardless of race.
How Screening and Vaccination Changed the Numbers
Two tools have dramatically reduced cervical cancer in countries that use them widely: the Pap test (and the newer HPV test) and the HPV vaccine.
Screening catches precancerous changes years before they become invasive cancer, giving doctors a window to remove abnormal cells with simple outpatient procedures. The 70% reduction in cervical cancer deaths in developed countries is almost entirely attributable to routine screening programs.
The HPV vaccine, available since 2006, is now showing its impact on the generation that received it. Among vaccinated teen girls, infections with the HPV types responsible for most cervical cancers dropped 88%. Among young adult women, those infections fell 81%. Precancerous cervical changes caused by the most dangerous HPV strains dropped 40% among vaccinated women. These are precancers that would have become invasive cancers in some of those women over the following 10 to 20 years, so the full effect on cancer rates is still unfolding.
Survival Rates by Stage
When cervical cancer is caught early, before it has spread beyond the cervix, the five-year survival rate is 91%. That drops to 60% once it has reached nearby tissues or lymph nodes, and to 19% when it has spread to distant parts of the body. The gap between those numbers is one of the strongest arguments for regular screening: catching it early changes the odds dramatically.
Most cervical cancers grow slowly. The progression from an initial HPV infection to precancerous changes to invasive cancer typically takes 10 to 20 years. That long timeline is exactly what makes screening so effective. A Pap or HPV test can detect the problem during those years of slow change, well before symptoms ever appear.
The Global Picture
The story outside high-income countries is starkly different. The vast majority of the 660,000 annual cases and 350,000 deaths occur in low- and middle-income countries where screening programs are limited or nonexistent and HPV vaccination coverage remains low. In parts of sub-Saharan Africa and Southeast Asia, cervical cancer is the leading cause of cancer death among women.
This disparity reinforces a key point: cervical cancer is largely preventable. In places with strong screening infrastructure and high vaccination rates, it has become uncommon. In places without those tools, it remains one of the deadliest cancers women face. The biology of the disease hasn’t changed. Access to prevention has.